TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03733210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE-NEO II camera
Description: Medical infrared camera manufactured by Hamamatsu Photonics KK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE-NEO II camera
Description: Medical infrared camera manufactured by Hamamatsu Photonics KK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIS-00 fluorescence imaging system (FIS)
Description: Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIS-00 fluorescence imaging system (FIS)
Description: Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Firefly Imaging System
Description: Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Firefly Imaging System
Description: Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IGP-ELVIS-v4 Macroscopic Specimen Imager
Description: Macroscopic specimen imager manufactured by LI-COR Biosciences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IGP-ELVIS-v4 Macroscopic Specimen Imager
Description: Macroscopic specimen imager manufactured by LI-COR Biosciences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vevo 3100 LAZR-X
Description: Photoacoustic ultrasound imaging system manufactured by VisualSonics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vevo 3100 LAZR-X
Description: Photoacoustic ultrasound imaging system manufactured by VisualSonics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pearl Triology Imaging System
Description: Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pearl Triology Imaging System
Description: Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Odyssey CLx Imaging System
Description: Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
Study: NCT00894595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knäkontroll, SISU Idrottsböcker©, Sweden, 2005
Description: The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
Study: NCT01317303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cTBS-PAS25
Description: 40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cTBS-iTBS
Description: 40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAS25
Description: PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: 190 seconds of intermittent theta-burst stimulation
Study: NCT01978483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB exposure

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: UVB exposure

Intervention type: DRUG
Group type: OTHER
Intervention: Diphenylcyclopropenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenylcyclopropenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenylcyclopropenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01171677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntenSati
Description: IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem.
Study: NCT01778959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Malyugin Ring
Description: insertion of a Malyugin Ring to stabilite the pupil during cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iris hooks
Description: insertion of iris retractors to stabilize the pupil during cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard OVD
Description: use of a standard cohesive OVD during cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OVD
Description: use of a highly cohesive OVD during cataract surgery
Study: NCT01341743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: patients will receive oral entecavir 1mg, daily for 104 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir, Adefovir
Description: patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir, Adefovir
Description: patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
Study: NCT00981903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin sodium
Description: Subcutaneous injection 175 U/Kg/day
Study: NCT03511001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-Cigarette Vs. Smoking as Usual
Description: 6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette Vs. Smoking as Usual
Description: 6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
Study: NCT02471313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] FMISO
Description: \[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
Study: NCT02706925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 443651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00600067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine/Topiramate
Description: phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
Study: NCT01003834

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized health screening
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized health screening
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized health screening
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized health screening
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized assessment
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized assessment
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized assessment
Description: Behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-delivered motivational intervention
Description: Behavioral intervention
Study: NCT02808767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
Study: NCT00600067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules, once daily, 28 weeks
Study: NCT03606486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tumor sample and blood draw

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01401023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: : Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
Study: NCT02960204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan
Study: NCT03706079

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT00647881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
Description: 25mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR™ Tablets 25 mg
Description: 25mg, single dose fed
Study: NCT02796469

Intervention type: DRUG
Intervention: Pentoxifylline
Study: NCT02960204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan
Study: NCT03733210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Odyssey CLx Imaging System
Description: Infrared fluorescent-imaging system manufactured by LI-COR Biosciences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leica fluorescence microscope
Description: Fluorescence microscope manufactured by Leica

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leica fluorescence microscope
Description: Fluorescence microscope manufactured by Leica
Study: NCT00301847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT05594303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologuos transplantation of bronchial basal cells
Description: Autologuos transplantation of bronchial basal cells
Study: NCT03566576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
Study: NCT03606486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lavage
Description: Undergo uterine lavage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pap Smear
Description: Undergo pap smear
Study: NCT02404168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine (brand Lamictal)
Description: an anti-epileptic drug (brand)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine (brand Lamictal)
Description: an anti-epileptic drug (brand)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine (generic Teva)
Description: an anti-epileptic drug (brand)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine (generic Teva)
Description: an anti-epileptic drug (brand)
Study: NCT02881736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroencephalographic,magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalographic,magnetic resonance imaging
Study: NCT02307448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Patients will receive weekly PRP treatments with standard of care.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive weekly standard of care.
Study: NCT04541082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC206
Description: ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
Study: NCT03566576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
Study: NCT02960204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01154439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
Study: NCT05115058

Intervention type: OTHER
Group type: OTHER
Intervention: relex Smile module
Study: NCT00495885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volinanserin (M100907)
Description: oral, one tablet taken around bedtime
Study: NCT00469833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
Study: NCT05110573

Intervention type: PROCEDURE
Intervention: pancreatoduodenectomy
Description: Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic

Intervention type: PROCEDURE
Intervention: pancreatoduodenectomy
Description: Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
Study: NCT05753514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT
Description: ESWT
Study: NCT03129542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Hydrochloride 10 milligrams
Description: Three doses taken every 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Three doses taken every 8 hours.
Study: NCT00363311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study: NCT03249194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct acting Anti-Viral Therapy using Epclusa or Zepatier
Description: All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
Study: NCT01027858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic-based exercise training
Description: Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON (control; usual care)
Description: Nutrition education and usual care as prescribed by neurologist
Study: NCT02014805

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
Study: NCT04364555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Description: Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/Klobetasol APL oral gel 0.025%
Description: Placebo/active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/placebo
Study: NCT00326599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT04273165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etravirine Tablets
Description: Daily etravirine BID with 100 or 200 tablets for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etravirine Tablets
Description: Daily etravirine BID with 100 or 200 tablets for 4 months
Study: NCT01508910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto-CD34+ cells
Description: 10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Diluent used to suspend Auto-CD34+ cells
Description: 10 intramyocardial injections of 0.2 mL per injection site of placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care for refractory angina
Study: NCT02099825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine and mifepristone
Description: All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine and mifepristone
Description: All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
Study: NCT02246010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose- free milk
Description: Lactose- free milk
Study: NCT03555877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg once daily as indicated in the SmPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg once daily as indicated in the SmPC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2,5mg once daily as indicated in the SmPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2,5mg once daily as indicated in the SmPC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25mg once daily as indicated in the SmPC
Study: NCT00495885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, one tablet taken around bedtime
Study: NCT03766971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 days of Tobacco Cessation
Description: Participants will be randomly assigned to 7 days of tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 days of Tobacco Cessation
Description: Participants will be randomly assigned to 7 days of tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 21 days of Tobacco Cessation
Description: Participants will be randomly assigned to 21 days of tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 21 days of Tobacco Cessation
Description: Participants will be randomly assigned to 21 days of tobacco cessation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will receive cannabis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will receive cannabis.
Study: NCT01761552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Reversal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine/Neostigmine
Study: NCT01037634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
Study: NCT02796469

Intervention type: DRUG
Intervention: Pentoxifylline

Intervention type: DRUG
Intervention: Corticosteroid

Intervention type: DRUG
Intervention: Corticosteroid
Study: NCT03124862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARM sensor
Description: Acoustic Monitoring sensor that monitors respiratory rate
Study: NCT04273581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg/d，qn，for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg/d，qn，for 14 days.
Study: NCT03510182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation